MedPath

Cytokinetics

🇺🇸United States
Ownership
-
Employees
564
Market Cap
$6.5B
Website
Clinical Trials
Related News

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Phase 2
Completed
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Drug: 25 mg Omecamtiv Mecarbil
Drug: Placebo
Drug: 37.5 mg Omecamtiv Mecarbil
Drug: 50 mg Omecamtiv Mecarbil
First Posted Date
2016-03-01
Last Posted Date
2021-07-27
Lead Sponsor
Cytokinetics
Target Recruit Count
81
Registration Number
NCT02695420
Locations
🇯🇵

Research Site, Shinagawa-ku, Tokyo, Japan

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Phase 2
Completed
Conditions
Spinal Muscular Atrophy
Interventions
Drug: Placebo
First Posted Date
2016-01-01
Last Posted Date
2020-08-31
Lead Sponsor
Cytokinetics
Target Recruit Count
70
Registration Number
NCT02644668
Locations
🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

University of California Irvine, Orange, California, United States

🇺🇸

Pediatric Neuromuscular Clinic Stanford University, Palo Alto, California, United States

and more 16 locations

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Placebo
First Posted Date
2015-11-10
Last Posted Date
2021-07-27
Lead Sponsor
Cytokinetics
Target Recruit Count
50
Registration Number
NCT02601001
Locations
🇯🇵

Research Site, Kagoshima-shi, Kagoshima, Japan

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

Phase 3
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo tablets
First Posted Date
2015-07-14
Last Posted Date
2020-09-09
Lead Sponsor
Cytokinetics
Target Recruit Count
744
Registration Number
NCT02496767
Locations
🇺🇸

St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 78 locations

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Phase 2
Completed
Conditions
Echocardiogram
Left Ventricular Systolic Dysfunction
Chronic Heart Failure
Left Ventricular Ejection Fraction
Modified Release Oral Formulation
History of Chronic Heart Failure
Pharmacokinetics
Interventions
Drug: Omecamtiv Mecarbil Swellable Core Technology F2
Drug: Placebo
Drug: Omecamtiv Mecarbil Matrix F1 Formulation
Drug: Omecamtiv Mecarbil Matrix F2 Formulation
First Posted Date
2013-02-08
Last Posted Date
2021-08-12
Lead Sponsor
Cytokinetics
Target Recruit Count
544
Registration Number
NCT01786512
Locations
🇬🇧

Research Site, London, United Kingdom

Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency

Phase 1
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2012-11-30
Last Posted Date
2021-07-30
Lead Sponsor
Cytokinetics
Target Recruit Count
13
Registration Number
NCT01737866
Locations
🇺🇸

Research Site, Orlando, Florida, United States

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Other: Placebo tablets
First Posted Date
2012-10-18
Last Posted Date
2020-03-31
Lead Sponsor
Cytokinetics
Target Recruit Count
711
Registration Number
NCT01709149
Locations
🇺🇸

Barrow Neurology, Phoenix, Arizona, United States

🇺🇸

University of California, San Diego, La Jolla, California, United States

🇺🇸

UC Irvine ALS & Neuromuscular Center, Orange, California, United States

and more 72 locations

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo
First Posted Date
2011-12-07
Last Posted Date
2019-05-03
Lead Sponsor
Cytokinetics
Target Recruit Count
27
Registration Number
NCT01486849
Locations
🇺🇸

University of California at San Francisco, Fresno Campus, Central California Neurological Institute, Fresno, California, United States

🇺🇸

Coordinated Clinical Research, La Jolla, California, United States

🇺🇸

University of California at Irvine, ALS and Neuromuscular Center, Orange, California, United States

and more 8 locations

A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers

Phase 1
Completed
Conditions
Heart Failure
Interventions
Drug: placebo
First Posted Date
2011-06-27
Last Posted Date
2015-10-14
Lead Sponsor
Cytokinetics
Target Recruit Count
35
Registration Number
NCT01380223
Locations
🇬🇧

ICON Development Solutions, Manchester, England, United Kingdom

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo (Part A)
Drug: CK-2017357 (Part A)
Drug: Placebo (Part B)
Drug: CK-2017357 (Part B)
First Posted Date
2011-06-22
Last Posted Date
2019-05-07
Lead Sponsor
Cytokinetics
Target Recruit Count
49
Registration Number
NCT01378676
Locations
🇺🇸

California Pacific Medical Center, San Francisco, California, United States

🇺🇸

Mayo Florida, Jacksonville, Florida, United States

🇺🇸

University of Kansas, Kansas City, Kansas, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy